Dr. Nathan Cooperman, emergency physician and prediction-rule pioneer, and Dr. Bret Burstein, pediatric emergency researcher and lead author of the 2025 JAMA study, discuss modern risk stratification for febrile young infants. They cover biomarker-driven rules (procalcitonin, ANC, UA), which infants were included or excluded, HSV considerations, urine collection nuances, and how to use shared decision-making to safely reduce LPs and antibiotics.
